title: Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate.
abstract: Gabapentin is an anticonvulsant that successfully treats many neuropathic pain syndromes, although the mechanism of its antihyperalgesic action remains elusive. This study aims to help delineate gabapentin's antihyperalgesic mechanisms. We assessed the effectiveness of gabapentin at decreasing mechanical and cold hypersensitivity induced in a rat model of neuropathic pain. Thus, we compared the effectiveness of pre- or post-treatment with systemic or intrathecal (i.t.) gabapentin at reducing the development and maintenance of the neuropathic pain symptoms. Gabapentin successfully decreased mechanical and cold hypersensitivity, both as a pretreatment and post-treatment. Furthermore, both i.t. and systemic administration of gabapentin were effective in reducing the behavioral hypersensitivity; however, the i.t. administration was superior to the systemic. We also examined gabapentin's effects at inhibiting hindpaw formalin-induced release of excitatory amino acids (EAAs) in the spinal cord dorsal horn (SCDH) both in naïve rats and in rats with neuropathic pain. We present the first evidence that gabapentin reduces the formalin-induced release of both glutamate and aspartate in SCDH. Furthermore, i.t. gabapentin reduces the enhanced noxious stimulus-induced spinal release of glutamate seen in neuropathic rats. These data suggest that gabapentin reduces neuropathic pain symptoms by inhibiting the release of glutamate in the SCDH.
authors.affiliation: Departments of Anesthesia, Neurology and Neurosurgery and Psychology, McGill University, Montreal, Canada. terence.coderre@mcgill.ca
authors.forename: Terence J
authors.initials: TJ
authors.lastname: Coderre
authors.forename: Naresh
authors.initials: N
authors.lastname: Kumar
authors.forename: Celeste D
authors.initials: CD
authors.lastname: Lefebvre
authors.forename: Jonathan S C
authors.initials: JS
authors.lastname: Yu
mesh_terms: D000588:Amines / Q000008:administration & dosage / Q000494:pharmacology*; D000700:Analgesics / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001224:Aspartic Acid / Q000378:metabolism; D002908:Chronic Disease; D003509:Cyclohexanecarboxylic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D005528:Foot; D000077206:Gabapentin; D018698:Glutamic Acid / Q000378:metabolism*; D007274:Injections, Intraperitoneal; D007278:Injections, Spinal; D008297:Male; D009437:Neuralgia / Q000378:metabolism / Q000503:physiopathology*; D051381:Rats; D020318:Rats, Long-Evans; D013116:Spinal Cord / Q000378:metabolism*; D013117:Spinal Cord Compression / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000588:Amines; D000700:Analgesics; D003509:Cyclohexanecarboxylic Acids; D018691:Excitatory Amino Acid Antagonists; D001224:Aspartic Acid; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin